Study of Acetazolamide to Treat Central Sleep Apnea in Adults Using Medication for Opioid Use Disorder

What this Trial Is About

This trial investigates patients with central sleep apnea CSA who are receiving medication for opioid use disorder MOUD such as methadone or buprenorphine. Researchers aim to evaluate whether acetazolamide, a drug known to improve CSA in other situations, can also improve CSA caused by these medications and lead to physiological changes that might reduce drug craving. The study is a phase 2, randomized, placebo-controlled trial designed to explore these effects. Participants with opioid-induced CSA will be randomly assigned to receive either acetazolamide 250 mg or a matching placebo pill taken orally each evening for 7 days. After 7 days of treatment, they will undergo an overnight sleep study to assess breathing during sleep and overall sleep quality. The study compares the effects of acetazolamide versus placebo on CSA in this population. During the study, participants will have assessments including overnight polysomnography, measures of autonomic nervous system tone, nocturnal arousal, anxiety, cognitive function, and drug craving. The primary outcome is the change in Central Apnea Index CAI after 7 days. Secondary outcomes include measurements like the low frequencyhigh frequency LFHF ratio and Apnea Hypopnea Index AHI. The total participation spans at least 7 days of treatment with sleep and physiological assessments to understand the impact of acetazolamide on these patients.

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder